Cellulitishttps://yo.wikipedia.org/wiki/Cellulitis
Cellulitis jẹ akoran kokoro-arun ti o kan awọn ipele inu ti awọ ara. Gẹgẹbi awọn ami ati awọn aami aisan, agbegbe irora ti pupa pọ si ni iwọn ni awọn ọjọ diẹ. Awọn aala ti agbegbe ti pupa ko ni iyasọtọ daradara ati pe awọ ara le jẹ wiwu. Agbegbe ikolu jẹ irora nigbagbogbo. Eniyan le ni ibà ati myagia.

Awọn ẹsẹ ati oju jẹ awọn aaye ti o wọpọ julọ ti o kan. Awọn okunfa ewu pẹlu isanraju, wiwu ẹsẹ, ati ọjọ ogbó. Awọn kokoro arun ti o wọpọ julọ jẹ streptococci ati Staphylococcus aureus.

Itọju jẹ deede pẹlu awọn egboogi ti a mu nipasẹ ẹnu, gẹgẹbi cephalexin, amoxicillin tabi cloxacillin. Ni ayika 95% eniyan dara julọ lẹhin ọjọ 7 si 10 ti itọju. Awọn ti o ni àtọgbẹ, sibẹsibẹ, nigbagbogbo ni awọn abajade ti o buru julọ.

Cellulitis jẹ ailera ti o wọpọ, ati ni United Kingdom, cellulitis jẹ idi fun 1.6% ti gbigba si ile-iwosan kan. Cellulitis ni ọdun 2015 yorisi nipa iku 16,900 ni agbaye.

Itọju - Oògùn OTC
Cellulitis ti ilọsiwaju nilo itọju pẹlu awọn oogun aporo ti a fun ni aṣẹ nipasẹ dokita nikan. Ti ọgbẹ naa ba nyara ni kiakia ati pe iba ati otutu ba tẹle, o ni imọran lati kan si dokita kan ni kete bi o ti ṣee.
Lilo ikunra oogun aporo lori-ni-counter si awọn egbo tete le ṣe iranlọwọ. Ti epo ikunra ba wa ni tinrin ju, o le ma ṣiṣẹ rara.
#Polysporin
#Bacitracin
#Betadine

Lo awọn olutura irora OTC bi acetaminophen lati rọ irora naa.
#Ibuprofen
#Naproxen
#Acetaminophen

Jeki ẹsẹ mọ ki o tọju ẹsẹ elere nitori ẹsẹ elere mu eewu cellulitis pọ si.

Itọju
#First-generation cephalosporins (e.g. Cefradine)
#Bacterial culture
#Third-generation cephalosporins (e.g. Cefditoren Pivoxil)
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
  • Ẹsẹ jẹ ipo ti o wọpọ fun Cellulitis.
  • Aṣoju ọran
  • Cellulitis - ipele iwosan
  • Cellulitis lori ẹsẹ osi. Ti o ba tan kaakiri, iba giga le waye, ti o yori si mọnamọna ti o lewu aye.
  • Nigbati ọgbẹ naa ba ni ilọsiwaju, hyperpigmentation lẹhin iredodo le han.
  • O le ṣẹlẹ nipasẹ egbo lori ọpẹ.
  • Aṣoju ọran
  • Ti alemo erythematous tutu ba tan kaakiri, Cellulitis yẹ ki o fura.
  • Bi Cellulitis ṣe n dara si, awọn sẹẹli awọ ara ti o ku le yọ kuro, o le di yun.
  • Pupọ Cellulitis wa pẹlu wiwu ati erythema ni agbegbe agbegbe. Sibẹsibẹ, ninu ọran alailẹgbẹ yii nibiti ko si erythema agbegbe, carcinoma cell squamous yẹ ki o tun fura si.
  • Aṣoju ọran
  • iwosan alakoso.
References Cellulitis 31747177 
NIH
Cellulitis jẹ akoran awọ ara kokoro arun ti o wọpọ. O kan lori awọn eniyan miliọnu 14 lọdọọdun ni Amẹrika. O nyorisi si bii $3. 7 bilionu ni awọn idiyele itọju ọkọ alaisan ati awọn ile-iwosan 650,000 ni ọdun kọọkan. Ni deede, cellulitis fihan bi igbona, agbegbe pupa lori awọ ara pẹlu wiwu ati rirọ. O ṣẹlẹ nipasẹ ikolu kokoro-arun lojiji ti o ma nfa igbona ni awọn ipele awọ-ara ti o jinlẹ ati àsopọ to wa nitosi. Ko si ikun tabi pus pẹlu ikolu yii. Beta-hemolytic streptococci, paapaa ẹgbẹ A streptococcus (Streptococcus pyogenes) , jẹ awọn ẹlẹṣẹ deede, atẹle nipa methicillin-sensitive Staphylococcus aureus.
Cellulitis is a common bacterial skin infection, with over 14 million cases occurring in the United States annually. It accounts for approximately 3.7 billion dollars in ambulatory care costs and 650000 hospitalizations annually. Cellulitis typically presents as a poorly demarcated, warm, erythematous area with associated edema and tenderness to palpation. It is an acute bacterial infection causing inflammation of the deep dermis and surrounding subcutaneous tissue. The infection is without an abscess or purulent discharge. Beta-hemolytic streptococci typically cause cellulitis, generally group A streptococcus (i.e., Streptococcus pyogenes), followed by methicillin-sensitive Staphylococcus aureus. Patients who are immunocompromised, colonized with methicillin-resistant Staphylococcus aureus, bitten by animals, or have comorbidities such as diabetes mellitus may become infected with other bacteria.
 Cellulitis: current insights into pathophysiology and clinical management 29219814
Cellulitis jẹ akoran kokoro arun ti awọ ara ati awọn tisọ rirọ. O ṣẹlẹ nigbati awọn ọran ba wa pẹlu idena aabo awọ ara, eto ajẹsara, tabi sisan ẹjẹ. Àtọgbẹ, isanraju, ati ọjọ ogbó ṣe alekun awọn aye ti cellulitis nipa ni ipa awọn agbegbe wọnyi. A tun wo awọn awari aipẹ lori ṣiṣe iwadii cellulitis , ti n ṣe afihan pataki ti iwadii aisan deede niwon awọn ipo bii aipe iṣọn-ẹjẹ, àléfọ, thrombosis iṣọn jinlẹ, ati gout nigbagbogbo ni idamu pẹlu cellulitis. Awọn egboogi ti a lo lati tọju cellulitis ni a yan ni pẹkipẹki lati dojukọ awọn kokoro arun ti o wọpọ laisi iwuri fun resistance aporo. A tun sọrọ nipa awọn egboogi titun ti a fọwọsi fun cellulitis. Cellulitis nigbagbogbo n pada wa nitori awọn okunfa eewu ti nlọ lọwọ ati ibajẹ si eto lymphatic.
Cellulitis is a bacterial infection of the skin and soft tissues. It happens when there are issues with the skin's protective barrier, the immune system, or blood circulation. Diabetes, obesity, and old age increase the chances of cellulitis by affecting these areas. We also look at recent findings on diagnosing cellulitis, highlighting the importance of accurate diagnosis since conditions like venous insufficiency, eczema, deep vein thrombosis, and gout are often confused with cellulitis. Antibiotics used to treat cellulitis are chosen carefully to target common bacteria without encouraging antibiotic resistance. We also talk about new antibiotics approved for cellulitis. Cellulitis often comes back because of ongoing risk factors and damage to the lymphatic system..
 Current Treatment Options for Acute Skin and Skin-structure Infections 30957166 
NIH
Ọpọlọpọ eniyan lọ si awọn ile-iwosan tabi awọn yara pajawiri fun awọn akoran awọ ara kokoro lojiji. Staphylococcus aureus ni akọkọ germ ti o nfa awọn akoran wọnyi, o si n lera lati tọju nitori diẹ ninu awọn igara ni o lodi si awọn egboogi ti o wọpọ.
Acute bacterial skin and skin-structure infections are a common reason for seeking care at acute healthcare facilities, including emergency departments. Staphylococcus aureus is the most common organism associated with these infections, and the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) has represented a considerable challenge in their treatment.
 Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus 32257966 
NIH
Staphylococcus aureus le pin si oriṣi meji ti o da lori idahun wọn si awọn oogun apakokoro: methicillin-sensitive Staphylococcus aureus (MSSA) , methicillin-resistant Staphylococcus aureus (MRSA) . Ni awọn ọdun diẹ sẹhin, nitori itankalẹ kokoro arun ati ilokulo awọn oogun aporo, ilodisi ti S. Aureus si awọn oogun ti n pọ si, ti o yori si ilosoke agbaye ni awọn oṣuwọn ikolu MRSA.
According to the sensitivity to antibiotic drugs, S. aureus can be divided into methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). In recent decades, due to the evolution of bacteria and the abuse of antibiotics, the drug resistance of S. aureus has gradually increased, the infection rate of MRSA has increased worldwide.
 Treatment of severe skin and soft tissue infections: a review 29278528 
NIH
To review the salient features of the management of severe skin and soft tissue infections (SSTIs), including toxic shock syndrome, myonecrosis/gas gangrene, and necrotizing fasciitis.